Clinical Report: STAAR Surgical Showcases EVO ICL Innovation and Clinical Insights
Overview
STAAR Surgical highlights the advancements and clinical applications of its EVO ICL technology at the 44th ESCRS Congress. The EVO ICL has received CE Mark approval and is indicated for patients up to 60 years of age.
Background
The EVO Implantable Collamer Lens (ICL) technology represents a significant advancement in the correction of myopia and astigmatism. With over four million units sold globally, the EVO ICL offers a viable surgical alternative for patients who may not be suitable candidates for laser procedures like LASIK. Its biocompatible design allows for reversibility.
Data Highlights
No numerical data presented in the article.
Key Findings
EVO ICL received CE Mark approval in Europe in 2011.
Indications for EVO ICL have expanded to include patients up to 60 years of age.
The EVO ICL can be used as a supplemental lens following cataract surgery.
STAAR Surgical will host small-group sessions at ESCRS to discuss practical surgical topics.
Future presentations will cover various aspects of ICL management and outcomes.
Clinical Implications
The EVO ICL provides an alternative for patients with moderate to high myopia, particularly those who are not candidates for LASIK.
Conclusion
The ongoing developments and discussions surrounding the EVO ICL at the ESCRS Congress highlight its role in refractive surgery.
